Predict your next investment

OncoResponse company logo
Corporation
HEALTHCARE | Biotechnology
oncoresponseinc.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series C | Alive

Total Raised

$103.1M

Last Raised

$40.6M | 7 mos ago

About OncoResponse

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.

OncoResponse Headquarter Location

1124 Columbia St Suite 300

Seattle, Washington, 98104,

United States

206-805-1600

Latest OncoResponse News

08:00 ET OncoResponse Announces Presentations at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021)

Oct 6, 2021

News provided by Share this article Share this article SEATTLE, Oct. 6, 2021 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced that it will present three abstracts at the upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting being held in Washington D.C. and virtually November 10-14, 2021. "We are pleased to be highlighting several preclinical findings at the SITC conference demonstrating the application of our propriety immunotherapy platform we are utilizing to discover and develop therapeutic antibodies that modulate the tumor microenvironment. This includes preclinical findings for our lead therapeutic candidate, OR2805, which has entered clinical development," said Clifford Stocks, Chief Executive Officer of OncoResponse. Details of the poster presentations are as follows: Title:  Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages Poster/Abstract Number: 271 Title:  Preclinical characterization of humanized anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression Poster/Abstract Number: 262 Date/Time: Saturday, November 13, 2021, 7:00 a.m. - 8:30 p.m. EST Title: Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression Poster/Abstract Number: 276 Date/Time: Saturday, November 13, 2021, 7:00 a.m. - 8:30 p.m. EST Poster presentations will be accessible in person and virtually. Onsite posters will be displayed in the SITC Poster Hall located in Hall E of the convention center. ePosters will be available for SITC attendees on Nov. 12 at 7 am ET and can be accessed on the SITC virtual meeting site. About OR2805 OR2805 is a fully human antibody discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy. This antibody binds to CD163 which is highly expressed on tumor associated macrophages (TAMs) that create an immunosuppressive tumor microenvironment and inhibit anti-tumor T-cell responses. High frequency of CD163-expressing TAMs generally predicts an unfavorable prognosis in solid tumors. OR2805 is designed to improve anti-tumor T-cell responses, by reversing the immunosuppression of TAMs, as a therapeutic strategy for monotherapy and in combination with CPI. About OncoResponse OncoResponse, Inc. is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company's lead candidate, OR2805, has entered clinical studies. Additional pipeline candidates that modulate suppressive macrophage activity are under development. OncoResponse is a privately held company backed by investment from MD Anderson Cancer Center, Rivervest Venture Partners, Qatar Investment Authority, Redmile Group, Magnetar Group, Yonjin Venture, Bering Capital, ARCH Venture Partners, Helsinn Investment Fund, Canaan Partners, GreatPoint Ventures, Takeda Ventures, Buchang Pharma (China), Alexandria Real Estate Equities and William Marsh Rice University. For more information please visit  www.oncoresponseinc.com and follow us on LinkedIn and Twitter . Media Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OncoResponse

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OncoResponse is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

OncoResponse Patents

OncoResponse has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/22/2020

6/15/2021

Monoclonal antibodies, Immune system, Clusters of differentiation, Immunology, Experimental cancer drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/22/2020

00/00/0000

Grant Date

6/15/2021

00/00/0000

Title

Subscribe to see more

Related Topics

Monoclonal antibodies, Immune system, Clusters of differentiation, Immunology, Experimental cancer drugs

Subscribe to see more

Status

Grant

Subscribe to see more

OncoResponse Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OncoResponse Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.